abstract |
The present invention relates to a combination of a peroxisome proliferator activated receptor (PPAR) activator and a benzoquinone and their use in the treatment and / or prevention of disorders characterized by endothelial dysfunction such as cardiovascular disease, stroke and myocardial infarction. According to a preferred embodiment of the invention, benzoquinone or a precursor thereof is a ubiquinone or precursor thereof, more preferably, coenzyme Q10 or a precursor thereof and the PPAR activator is a fibrate or a thiazolidinedione, more preferably fenofibrate. |